Title: Natural Immunity Transparency Act
Policy area: Health

Summary:
Natural Immunity Transparency Act
This bill requires the Department of Health and Human Services to report within 30 days of the bill's enactment to Congress concerning natural immunity to COVID-19.
In particular, the report must compare certain outcomes for individuals who recovered from a COVID-19 infection without having received the vaccination and individuals who received the vaccination.

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. 3581 Introduced in Senate (IS)]

<DOC>






117th CONGRESS
  2d Session
                                S. 3581

   To direct the Secretary of Health and Human Services to submit to 
Congress a report on COVID-19 natural immunity, and for other purposes.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                            February 3, 2022

Mr. Braun (for himself and Mr. Lankford) introduced the following bill; 
     which was read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL


 
   To direct the Secretary of Health and Human Services to submit to 
Congress a report on COVID-19 natural immunity, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Natural Immunity Transparency Act''.

SEC. 2. REPORT ON COVID-19 NATURAL IMMUNITY.

    (a) In General.--Not later than 30 days after the date of enactment 
of this Act, the Secretary of Health and Human Services shall submit to 
Congress a report that contains--
            (1) the number of individuals who recovered from a COVID-19 
        infection, and never received a COVID-19 vaccine, during the 
        period beginning on January 1, 2020, and ending on such date of 
        enactment, and who subsequently--
                    (A) died from a COVID-19 infection;
                    (B) were hospitalized from a COVID-19 infection;
                    (C) had an additional confirmed case of COVID-19; 
                or
                    (D) transmitted SARS-CoV-2 to another person or 
                persons while reinfected; and
            (2) the number of individuals who received all recommended 
        doses of a COVID-19 vaccine during the period beginning on 
        December 14, 2020, and ending on such date of enactment, and 
        who subsequently--
                    (A) died from a COVID-19 infection;
                    (B) were hospitalized from a COVID-19 infection; or
                    (C) had a confirmed breakthrough case.
    (b) Definitions.-- In this section:
            (1) Breakthrough case.--The term ``breakthrough case'', 
        with respect to a case of COVID-19, means the detection of 
        SARS-CoV-2 RNA or antigen in a respiratory specimen collected 
        from an individual at least 14 days after the date on which 
        such individual received all recommended doses of a COVID-19 
        vaccine.
            (2) COVID-19 vaccine.--The term ``COVID-19 vaccine'' means 
        a vaccine for COVID-19 that has been licensed under section 351 
        of the Public Health Service Act (42 U.S.C. 262) or authorized 
        for emergency use under section 564 of the Federal Food, Drug, 
        and Cosmetic Act (21 U.S.C. 360bbb-3).
                                 <all>